<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40063">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01750723</url>
  </required_header>
  <id_info>
    <org_study_id>H-3-2012-137</org_study_id>
    <nct_id>NCT01750723</nct_id>
  </id_info>
  <brief_title>Acetazolamide's Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow</brief_title>
  <official_title>Basic Research on AcetazolamideÂ´s Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow in a Humane Experimental Headache Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will research the hypothesis that the drug Acetazolamide
      induce headache and dilation of cerebral arteries and increase the cerebral blood flow in
      the areas of the brain supplied by these arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate headache score and accompanying symptoms during and after infusion of
      acetazolamide.

      With magnetic resonance imaging the investigators will investigate changes in regional
      cerebral blood flow (rCBF) in the area supplied by middle cerebral artery (MCA), diameter of
      MCA, the Internal carotic artery (ICA), the superficial temporal artery (STA) and the Medial
      Meningeal artery (MMA).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Headache scores</measure>
    <time_frame>24 h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison between Acetazolamide and placebo (saline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Artery circumference</measure>
    <time_frame>Baseline, 30 min and 60 min</time_frame>
    <safety_issue>No</safety_issue>
    <description>Acetazolamide induced changes in intracranial artery circumference before and after infusions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral blood flow</measure>
    <time_frame>Baseline, 30 and 60 min.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Acetazolamide induced changes in cerebral blood flow.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Headache</condition>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetazolamide 1 g in 10 ml saline, i.v. infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline, 10 ml i.v. infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>1 g diluted in 10 ml saline, i.v. bolus injection.</description>
    <arm_group_label>Acetazolamide</arm_group_label>
    <other_name>Diamox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Aged 18-40

          -  50-100 kg

          -  Fertile women must use safe contraceptives (IUD, oral contraceptives, surgical
             sterilisation and long lasting gestagen.

        Exclusion Criteria:

          -  Tension type headache more than once/month

          -  Other primary headaches

          -  Daily medication except contraceptives

          -  Drug taken within 4 times the halflife for the specific drug except contraceptives

          -  Pregnant or lactating women

          -  Exposure to radiation within the last year

          -  Headache within the last 24 hours before start of trial

          -  Hypertension

          -  Hypotension

          -  Respiratory or cardiac disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nanna Arngrim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Copenhagen</city>
        <state>Glostrup</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology</name>
      <address>
        <city>Copenhagen</city>
        <state>Glostrup</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 8, 2013</lastchanged_date>
  <firstreceived_date>December 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Nanna Arngrim</investigator_full_name>
    <investigator_title>MD, medical doctor</investigator_title>
  </responsible_party>
  <keyword>Acetazolamide</keyword>
  <keyword>Headache</keyword>
  <keyword>Migraine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
